HaploX Showcases Cutting-Edge Multi-Omics and Liquid Biopsy Solutions for Colorectal Cancer at Prestigious Indonesian Oncology Conference

SHENZHEN, China – HaploX, a leading precision oncology company, is proud to announce its participation in the upcoming Annual Conference for Indonesia Oncology Association (IOA) 2025, held from November 7th to 9th in Yogyakarta, Indonesia. The company's presence at this premier event underscores its commitment to advancing cancer care and fostering scientific exchange in Southeast Asia.

A key highlight of HaploX's involvement will be an oral presentation delivered by Dr. Shi-Fu Chen, Chief Scientific Officer of HaploX. His presentation, titled "Precision Colorectal Cancer Diagnosis and Treatment with Multi-Omics and Liquid Biopsy," is scheduled for November 9, 2025, at 10:50 - 11:10 AM. The session will delve into the transformative potential of integrating multi-omics data with liquid biopsy technologies to revolutionize the management of colorectal cancer.

Colorectal cancer remains a significant health burden globally and in Indonesia. Dr. Chen's presentation will focus on how HaploX's innovative approaches enable more precise diagnosis, real-time monitoring of treatment response, and the detection of minimal residual disease (MRD). By analyzing circulating tumor DNA (ctDNA) through liquid biopsy—a less invasive alternative to traditional tissue biopsies—and combining it with comprehensive multi-omics profiling, clinicians can gain unprecedented insights into tumor dynamics and heterogeneity.

"We are honored to share our latest research and clinical insights at the Indonesia Oncology Association Annual Conference," said Dr. Shi-Fu Chen. "Our work in multi-omics and liquid biopsy is paving the way for a new era of personalized medicine in oncology. We believe these technologies hold immense promise for improving patient outcomes in colorectal cancer and other solid tumors, and we are excited to collaborate with the medical community in Indonesia to bring these advanced diagnostic solutions to patients."

The Annual Conference for the Indonesia Oncology Association is a major gathering of leading oncologists, researchers, and healthcare professionals from across the archipelago and the region. It serves as a vital platform for discussing the latest advancements, challenges, and future directions in cancer treatment and research.

HaploX's participation in this conference reinforces its mission to bridge the gap between groundbreaking genomic science and clinical practice worldwide.